Previous 10 | Next 10 |
Pacira BioSciences (PCRX) reports October net product sales of EXPAREL and iovera of $40.7M and $1M, respectively.The company’s 2020 product sales have been negatively impacted by the COVID-19 pandemic, which mandated postponement or suspension in the scheduling of elective surgical pr...
PARSIPPANY, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net product sales of EXPAREL ® (bupivacaine liposome injectable suspension) and i...
PARSIPPANY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Jefferies Virtual London Healthcare Conference at 2:05 PM GMT (9:05 AM ET) on Tuesday, November 17, 2020. Live audio of the virtual event...
Image source: The Motley Fool. Pacira BioSciences, Inc. (NASDAQ: PCRX) Q3 2020 Earnings Call Oct 29, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Pacira BioSciences, Inc. (PCRX) Q3 2020 Earnings Call Transcript ...
Pacira BioSciences, Inc. (PCRX) Q3 2020 Earnings Conference Call October 29, 2020 08:30 ET Company Participants Susan Mesco - Head of Investor Relations David Stack - Chairman & Chief Executive Officer Charlie Reinhart - Chief Financial Officer Conference Call Participants Randall Stanick...
The following slide deck was published by Pacira BioSciences, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Pacira BioSciences, Inc. 2020 Q3 - Results - Earnings Call Presentation
Pacira BioSciences (PCRX): Q3 Non-GAAP EPS of $0.68 beats by $0.03; GAAP EPS of $2.94 beats by $2.63.Revenue of $117.48M (+12.2% Y/Y) beats by $1.53M.Press Release For further details see: Pacira BioSciences EPS beats by $0.03, beats on revenue
-- EXPAREL average daily sales at 110% of the prior year for the third quarter-- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain mana...
Pacira BioSciences (NASDAQ:PCRX) is scheduled to announce Q3 earnings results on Thursday, October 29th, before market open.The consensus EPS Estimate is $0.65 (+35.4% Y/Y) and the consensus Revenue Estimate is $115.95M (+10.7% Y/Y).Over the last 2 years, PCRX has beaten EPS estimates 88% of ...
--The Pacira Innovation and Training Center of Tampa will provide clinicians with a flexible environment for hands-on learning-- PARSIPPANY, N.J., and TAMPA, Fla., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NADSAQ: PCRX), the leading provider of non-opioid pain manageme...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday July 30, 2024. Following the release, the company will host a live conference call and webc...
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...